AbbVie announces data from MAGELLAN-1 study of ABT-493+ ABT-530 for treatment of hepatitis C

AbbVie announced that from the MAGELLAN-1 study, 91% (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. Additionally, 86% (n=19/22) of GT1 patients who received ABT-493 and ABT-530 without RBV, achieved SVR12. SVR12 was achieved in 95% of patients with and without RBV (n=20/21, n=19/20; respectively) in a modified intent-to-treat analysis, excluding patients who did not achieve SVR for reasons other than virologic failure. The results were evaluated in the ongoing MAGELLAN-1 study of AbbVie's once-daily, investigational, pan-genotypic regimen of co-formulated ABT-493 (300mg) and ABT-530 (120mg) for the retreatment of non-cirrhotic patients with GT1 chronic HCV who have failed previous therapy with DAAs. These data were presented at The International Liver Congress (ILC) 2016 in Barcelona, Spain. No patients discontinued treatment due to adverse events, and two patients experienced virologic failure, one from each arm.